drugset / Trial / NCT04249947

P-PSMA-101 CAR-T Cells in the Treatment of Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Advanced Salivary Gland Cancers (SGC)

NCT04249947

Phase 1 Terminated 40 enrolled Poseida Therapeutics, Inc.
Non-randomizedSequentialOpen-labelTreatment

Summary

An open-label, multi-center, single and cyclic ascending dose study of P-PSMA-101 autologous CAR-T cells in patients with mCRPC and SGC.

Timeline

Start
2020-02-28
Primary completion
2024-09-30
Completion
2024-09-30

Drugs

EvaluationDrugModalityDoseRoute
Subject P-PSMA-101 CAR-T cells Cell therapy Intravenous
Background Rimiducid Other / unclassified